Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 6/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | ERN1 | O75460 | 2/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29858635 | 1.00 | TTR (0.50) | TTRPDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL2046728 | 0.86 | PDGFRB (0.49) | TTRPDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL31159174 | 0.86 | PDGFRB (0.49) | TTRPDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL4022732 | 0.86 | PDGFRB (0.46) | TTRPDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL913705 | 0.86 | PDGFRB (0.46) | TTRPDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL7028476 | 0.84 | ERN1 (0.56) | PDGFRBFGFR1PDGFRAFLT1FGFR3 | |
| SCHEMBL25087425 | 0.83 | TPMT (0.46) | TTRPDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL4017244 | 0.83 | PDGFRB (0.44) | TTRPDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL505648 | 0.83 | ALDH1A1 (0.45) | TTRPDGFRBFGFR1PDGFRAFLT1 | |
| SCHEMBL4301550 | 0.83 | MEN1 (0.52) | PDGFRBFGFR1PDGFRAFLT1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112718002-A | Preparation method of nicarparii intermediate | 杭州君领医药科技有限公司 | 2021-04-30 | — | — | CN | claimed |
| CN-110078625-B | Method for preparing intermediate for ovarian cancer medicine | 张磊 | 2020-04-14 | — | — | CN | claimed |
| US-12398097-B2 | WDR5-MYC inhibitors | VANDERBILT UNIVERSITY (US) | 2025-08-26 | — | — | US | disclosed |
| US-20220289673-A1 | WDR5-MYC INHIBITORS | VANDERBILT UNIVERSITY | 2022-09-15 | — | — | US | disclosed |
| CN-112718002-A | Preparation method of nicarparii intermediate | 杭州君领医药科技有限公司 | 2021-04-30 | — | — | CN | disclosed |
| CN-112718002-A | Preparation method of nicarparii intermediate | 杭州君领医药科技有限公司 | 2021-04-30 | — | — | CN | disclosed |
| WO-2021021951-A1 | WDR5-MYC INHIBITORS | VANDERBILT UNIVERSITY (US) | 2021-02-04 | — | — | WO | disclosed |
| CN-110229162-B | Simple preparation method of Ruipab | 新发药业有限公司 | 2020-08-11 | — | — | CN | disclosed |
| CN-110078625-B | Method for preparing intermediate for ovarian cancer medicine | 张磊 | 2020-04-14 | — | — | CN | disclosed |
| CN-110105219-B | Method for preparing intermediate for antiviral drug | 张磊 | 2020-04-14 | — | — | CN | disclosed |
| CN-101998959-B | Benzoxazole carboxamide inhibitors of poly(ADP-ribose)polymerase (PARP) | BIOMARIN PHARM INC | 2013-08-28 | — | — | CN | disclosed |
| WO-2009099736-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| US-7323562-B2 | Method of preparing poly(ADP-ribose) polymerases inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323562-B2 | Method of preparing poly(ADP-ribose) polymerases inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323562-B2 | Method of preparing poly(ADP-ribose) polymerases inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| EP-1794163-A1 | METHOD OF PREPARING POLY(ADP-RIBOSE) POLYMERASES INHIBITORS | Pfizer, Inc. (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006033003-A1 | METHOD OF PREPARING POLY(ADP-RIBOSE) POLYMERASES INHIBITORS | PFIZER, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| WO-2006033003-A1 | METHOD OF PREPARING POLY(ADP-RIBOSE) POLYMERASES INHIBITORS | PFIZER, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063926-A1 | Method of preparing poly(ADP-ribose) polymerases inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289673-A1 | WDR5-MYC INHIBITORS | MYC, WDR5, MYCBP | TTR 4242/4885PDGFRB 4543/4885FGFR1 1802/4885 |
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | TTR 4434/4885PDGFRB 596/4885FGFR1 2576/4885 |
| US-20060063926-A1 | Method of preparing poly(ADP-ribose) polymerases inhibitors | PARP1, PARP11, PARP2 | TTR 4672/4885PDGFRB 519/4885FGFR1 3114/4885 |
| US-12398097-B2 | WDR5-MYC inhibitors | MYC, WDR5, MYCBP | TTR 4242/4885PDGFRB 4543/4885FGFR1 1802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.